Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: BDB-001 Injection
- Registration Number
- NCT05093855
- Lead Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Brief Summary
The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
- Subjects who signed the informed consent to participate in the STS-BDB001-06 clinical study and completed all follow-up of the study as required by the protocol, or who withdrew early due to treatment failure or other objective reasons and completed the early withdrawal visit (at least 4 weeks of treatment)
- Never participated in the clinical study of STS-BDB001-06；
- Subjects withdrew from the STS-BDB001-06 clinical study due to an intolerable adverse event related to the study drug.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Treatment group BDB-001 Injection -
- Primary Outcome Measures
Name Time Method Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point Week 8 The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group)，IHS4 Score=(Nodule Count) + (Abscess Count\*2) + (Draining Tunnel Count \*4).
IHS4 score uses a range grades:
Mild=0-3; Moderate=4-10; Severe ≥11.
- Secondary Outcome Measures
Name Time Method Change in Hidradenitis Suppurativa Clinical Response (HiSCR) from Day 0 by time point From Day 0 until Day 56 The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.
Change in Dermatology Life Quality Index (DLQI) score from Day 0 by time point From Day 0 until Day 56 A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.
Safety of BDB-001 injection in the treatment of patients with HS will be assessed From Day 0 until Day 77 Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time point From Day 0 until Day 56 The International Hidradenitis Suppurativa Severity Score 4 (IHS4: developed by the European Hidradenitis Suppurativa Foundation Investigator Group)，IHS4 Score=(Nodule Count) + (Abscess Count\*2) + (Draining Tunnel Count \*4).
IHS4 score uses a range grades:
Mild=0-3; Moderate=4-10; Severe ≥11.Change in modified Sartorius Score (mSS) from Day 0 by time point From Day 0 until Day 56 The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.
Changes of active lesions (number of inflammatory nodules, abscesses, fistulas, and abscess overflow score) from Day 0 by time point. From Day 0 until Day 56 7. Change in Dermatology visual analog scale (VAS) score from Day 0 by time point. From Day 0 until Day 56] Change in Hidradenitis suppurativa-Physician Global Assessment (HS-PGA) score from Day 0 by time point From Day 0 until Day 56 Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA)classifies patients' severity into six categories:clear, minimal, mild, moderate, severe, and very severe, based on the number and quality of inflammatory lesions.
Trial Locations
- Locations (15)
Peking University First Hospital
🇨🇳Beijing, Beijing, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
🇨🇳Beijing, Beijing, China
The Third Affiliated Hospital of Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Chinese Academy of Medical Sciences and Peking Union Medical College
🇨🇳Nanjing, Jiangsu, China
Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
🇨🇳Beijing, Beijing, China
Xiangya Hospital, Central South University
🇨🇳Changsha, Hunan, China
Union Hospital Tongji Medical College Huazong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The First Hospital of Jilin Universitv
🇨🇳Changchun, Jilin, China
The Second Affiliated Hospital of Air Force Medical University
🇨🇳Xi'an, Shaanxi, China
The First Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
The Second Affiliated Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, Shaanxi, China
Huashan Hospital of Fudan University
🇨🇳Shanghai, Shanghai, China
Qilu Hospital of Shandong University
🇨🇳Jinan, Shandong, China
Shanghai Skin Disease Hospital
🇨🇳Shanghai, Shanghai, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China